Completed PHASE3 INTERVENTIONAL NCT00005589

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy

Sponsor: EBMT Solid Tumors Working Party

Conditions Lymphoma

Interventions bone marrow ablation with stem cell support carmustine cyclophosphamide cytarabine etoposide filgrastim melphalan peripheral blood stem cell transplantation rituximab

Updated 6 times since 2017 Last updated: Sep 16, 2013 Started: Oct 31, 1999 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Lymphoma and is currently completed. EBMT Solid Tumors Working Party leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EBMT Solid Tumors Working Party
Lymphoma Trials Office

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalborg, Denmark , Aberdeen, United Kingdom , Adelaide, Australia , Alicante, Spain , Angers, France , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Auckland, New Zealand , Augsburg, Germany and 99 more locations